StreetInsider.com News Articles

Form 8-K Aspire Biopharma Holding For: Jun 12

Fri, 12 Jun 2026 10:26:00 -0400

si-local-file:///var/storage/secattach/20260612/26639159.html

Form 8-K Aspire Biopharma Holding For: Jun 12

Fri, 12 Jun 2026 10:26:00 -0400

si-local-file:///var/storage/secattach/20260612/26639159.html

Aspire Biopharma to acquire automotive supplier for $30 million

Fri, 12 Jun 2026 08:31:13 -0400

Aspire Biopharma Holdings Inc. (NASDAQ: ASBP) signed a definitive share purchase agreement to acquire Dura Driver Control Systems for $30 million in cash, according to a company statement.

The acquisition involves purchasing 100% of the issued and outstanding shares of DCS, an automotive driver control systems manufacturer. DCS will become a wholly owned subsidiary of Aspire following the transaction's completion.

DCS generated revenue of more than $200 million for fiscal year 2025, with net income exceeding $17 million and adjusted EBITDA of more than $22 million, based on unaudited figures. The company operates 11 manufacturing facilities across North America, Europe, and Asia.

The

Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Reven

Fri, 12 Jun 2026 08:30:00 -0400

Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems
Acquisition significantly accelerates Aspire's revenue, earnings growth and cash flow profile
Strategically diversifies Aspire's revenue streams
Opportunity to drive significant shareholder value creation and enhance long-term capital allocation optionality
Company does not anticipate procuring new equity financing to consummate the transaction

ESTERO, FL / ACCESS Newswire / June 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced the signing of a definitive Share Purchase Agreement ("SPA") for the acquisition of

Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Reven

Fri, 12 Jun 2026 08:30:00 -0400

Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems
Acquisition significantly accelerates Aspire's revenue, earnings growth and cash flow profile
Strategically diversifies Aspire's revenue streams
Opportunity to drive significant shareholder value creation and enhance long-term capital allocation optionality
Company does not anticipate procuring new equity financing to consummate the transaction

Aspire Biopharma authorizes $5 million share buyback program

Thu, 28 May 2026 08:31:19 -0400

Aspire Biopharma Holdings Inc. (NASDAQ: ASBP) announced its board of directors authorized a $5 million share repurchase program, according to a shareholder letter from Chief Executive Officer Kraig Higginson.

The biopharmaceutical company recently completed the second tranche of a preferred stock private placement that generated approximately $21 million in net proceeds. The company stated it has returned to full compliance with Nasdaq's stockholders' equity requirements.

Aspire filed four provisional patent applications in early 2026 for sublingual powder formulations of generic drugs including Alprazolam, Clopidogrel, Ondansetron, and Meclizine. The filings occurred between January and February 2026 and expand the company's drug delivery technology

Aspire Biopharma Issues Shareholder Letter

Thu, 28 May 2026 08:30:00 -0400

ESTERO, FL / ACCESS Newswire / May 28, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today issued the following letter to shareholders from Chief Executive Officer Kraig Higginson.

Dear Fellow Shareholders,

2026 is shaping up to be a defining year for Aspire Biopharma Holdings. We are moving with speed to transform our clinical pipeline into commercial reality, broadening the market reach of our high growth consumer segment, while simultaneously diversifying our business through a proposed strategic acquisition.

Capital Market Milestones

Our Board of

Aspire Biopharma Issues Shareholder Letter

Thu, 28 May 2026 08:30:00 -0400

Dear Fellow Shareholders,

Capital Market Milestones

Our Board of

Aspire Biopharma partners with EoS Fitness for caffeine product distribution

Wed, 27 May 2026 08:30:54 -0400

Aspire Biopharma Holdings Inc. (NASDAQ: ASBP) announced a partnership between its subsidiary Buzz Bomb Caffeine Company and EoS Fitness to distribute caffeine products to gym members across more than 225 locations nationwide.

The partnership operates through EoS Fitness's Flex Deals affiliate program, which connects gym members with various brands. Buzz Bomb's 50mg sublingual caffeine stick packs will be marketed to EoS members through in-gym television advertising, mobile app offers, and on-site product demonstrations.

Buzz Bomb produces dry powder caffeine products delivered in single-serving stick packs that dissolve under the tongue. The company currently offers four flavors: Tropical Fruit, Mixed Berry, Peach Mango,

Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members

Wed, 27 May 2026 08:30:00 -0400

ESTERO, FL / ACCESS Newswire / May 27, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire" or the "Company") wholly owned subsidiary Buzz Bomb Caffeine Company LC is proud to announce a strategic partnership with EoS Fitness, the High Value. Low Price.^® (HVLP) gym chain with more than 225 locations open or on the way nationwide. Through the EoS Flex Deals affiliate program, BUZZ BOMB^™ 's lineup of 50mg sublingual caffeine stick packs will now be available to an expansive community of health-conscious gym members.

The

Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members

Wed, 27 May 2026 08:30:00 -0400

The

Form 10-Q Aspire Biopharma Holding For: Mar 31

Fri, 15 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260515/26505936.html

Form 10-Q Aspire Biopharma Holding For: Mar 31

Fri, 15 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260515/26505936.html

Form SCHEDULE 13G Aspire Biopharma Holding Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC

Fri, 15 May 2026 06:44:00 -0400

si-local-file:///var/storage/secattach/20260515/26498993.html

Form SCHEDULE 13G Aspire Biopharma Holding Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC

Fri, 15 May 2026 06:44:00 -0400

si-local-file:///var/storage/secattach/20260515/26498993.html

Form 8-K Aspire Biopharma Holding For: May 11

Thu, 14 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260514/26494685.html

Form 8-K Aspire Biopharma Holding For: May 11

Thu, 14 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260514/26494685.html

Form SCHEDULE 13G/A Aspire Biopharma Holding Filed by: ARDSLEY ADVISORY PARTNERS LP

Wed, 13 May 2026 13:01:00 -0400

si-local-file:///var/storage/secattach/20260513/26484656.html

Form SCHEDULE 13G/A Aspire Biopharma Holding Filed by: ARDSLEY ADVISORY PARTNERS LP

Wed, 13 May 2026 13:01:00 -0400

si-local-file:///var/storage/secattach/20260513/26484656.html

Form DEFR14A Aspire Biopharma Holding

Tue, 12 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260512/26478680.html

Form DEFR14A Aspire Biopharma Holding

Tue, 12 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260512/26478680.html

Form DEF 14A Aspire Biopharma Holding For: May 08

Mon, 11 May 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260511/26465785.html

Form DEF 14A Aspire Biopharma Holding For: May 08

Mon, 11 May 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260511/26465785.html

Aspire Biopharma to implement 1-for-30 reverse stock split May 11

Thu, 07 May 2026 11:00:12 -0400

Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) will implement a one-for-thirty reverse stock split of its common stock effective May 11, 2026, at 12:01 AM Eastern Time, according to a company statement.

The reverse split aims to bring the company into compliance with Nasdaq's minimum bid price requirement for maintaining its listing. Trading will continue under the existing symbol "ASBP" on a post-reverse split basis. The new CUSIP number will be 738920305.

Aspire's stockholders approved the reverse split proposal at a special meeting on April 10, 2026, authorizing the board of directors to implement the action. The board approved the 1-for-30 ratio on

Aspire Biopharma to implement 1-for-30 reverse stock split

Thu, 07 May 2026 11:00:12 -0400

Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) announced it will effect a one-for-thirty reverse stock split of its common stock on May 11, 2026, at 12:01 AM Eastern Time before trading opens on the Nasdaq Capital Market.

The reverse split aims to bring the company into compliance with Nasdaq's minimum bid price requirement for maintaining its listing. The stock will continue trading under the symbol "ASBP" following the split, with a new CUSIP number of 738920305.

Aspire's stockholders approved the reverse split proposal at a special meeting on April 10, 2026. The company's board of directors subsequently approved the 1-for-30 ratio on April